ICN Group Profitable In Second Quarter

25 September 1994

ICN Pharmaceutical says that its three companies, ICN Biomedicals, SPI Pharmaceuticals, and Viratek Inc, were profitable in the second quarter ended June 30, 1994.

SPI Pharmaceuticals, which contributed 83% of the combined sales of the ICN group, achieved net income of $5.2 million, worldwide sales of $79 million, and earnings per share of $0.25.

ICN Biomedicals, which is a biotechnology research company accounting for 16% of the group's combined sales, posted net income of $536,000, sales of $15.2 million and EPS of $0.06.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight